# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

#### Notes:

- Saxenda is covered under the prescription drug benefit for weight loss ONLY for Kaiser
   Northwest members with coverage for medications used to treat weight loss. Others pay member cash price.
- Contact Pharmacy Services in your home region to confirm your benefits for weight loss medications.
- Quantity Limits: Yes
- Adequate trial is defined as a 3-month treatment duration
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria for adult patients for chronic weight management</u>: Nonformulary <u>Iiraglutide</u> (Saxenda) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; AND
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis for chronic weight management; AND
- Patient is 18 years of age or older; AND
- Patient's current weight and BMI are documented in the encounter in which liraglutide (Saxenda) is ordered; AND
- Patient is currently following a diet and exercise program; AND
- BMI greater than or equal to 30 kg/m<sup>2</sup> or BMI greater than or equal to 27 kg/m<sup>2</sup> AND has at least one of the following comorbid conditions documented:
  - Hypertension
  - Diabetes
  - o Hyperlipidemia

### -AND-

- Patient has failed an adequate trial<sup>^</sup> to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - o phentermine
  - o diethylpropion
  - o topiramate
  - o phentermine + topiramate or phentermine/topiramate (Qsymia)
  - naltrexone + bupropion or naltrexone/bupropion (Contrave)

kp.org

Revised: 5/8/25 Effective: 7/3/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

#### -AND-

 Patient has then failed an adequate trial or has an allergy, intolerance, or contraindication to semaglutide (Ozempic/Wegovy)

<u>Initiation (new starts) criteria for pediatric patients for obesity:</u> Non-formulary <u>liraglutide (Saxenda)</u> will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; AND
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis of class 2 or class 3 obesity; AND
- Patient is 12 to 17 years of age and is at least Tanner 2; AND
- Patient's current weight and BMI are documented within the last month from the date in which liraglutide (Saxenda) is ordered; AND
- Patient is currently following a diet and exercise program AND
- BMI greater than or equal to 35 kg/m<sup>2</sup> or greater than or equal to 120% of the 95<sup>th</sup> percentile

### -AND-


- Patient has failed an adequate trial<sup>^</sup> to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - o topiramate
  - o phentermine + topiramate or phentermine/topiramate (Qsymia)

### -AND-

 Patient has then failed an adequate trial or has an allergy, intolerance, or contraindication to semaglutide (Ozempic/Wegovy)

kp.org

Revised: 5/8/25 Effective: 7/3/25





# Criteria-Based Consultation Prescribing Program KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR DRUG COVERAGE

## liraglutide (Saxenda)

Continued use criteria (every 12 months) for patients previously reviewed and approved when used for chronic weight management/obesity: Non-formulary liraglutide (Saxenda) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient's updated weight and BMI are recently documented; AND
- Achieved and maintained 5% or greater weight loss after starting liraglutide (Saxenda)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary <u>liraglutide</u>
(Saxenda) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; AND
- Patient is using for chronic weight management/obesity

kp.org

Revised: 5/8/25 Effective: 7/3/25

